Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma | Zendy

Henk M. Lokhorst | Zendy; Torben Plesner | Zendy; Jacob P. Laubach | Zendy; Hareth Nahi | Zendy; Peter Gimsing | Zendy; Markus Hansson | Zendy; Monique C. Minnema | Zendy; Ulrik Lassen | Zendy; Jakub Krejcik | Zendy; Antonio Palumbo | Zendy; Niels W.C.J. van de Donk | Zendy; Tahamtan Ahmadi | Zendy; Imran Khan | Zendy; Clarissa Uhlar | Zendy; Jianping Wang | Zendy; A. Kate Sasser | Zendy; Nedjad Losic | Zendy; Steen Lisby | Zendy; Linda Basse | Zendy; Nikolai C. Brun | Zendy; Paul G. Richardson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Author(s) -

Henk M. Lokhorst,

Torben Plesner,

Jacob P. Laubach,

Hareth Nahi,

Peter Gimsing,

Markus Hansson,

Monique C. Minnema,

Ulrik Lassen,

Jakub Krejcik,

Antonio Palumbo,

Niels W.C.J. van de Donk,

Tahamtan Ahmadi,

Imran Khan,

Clarissa Uhlar,

Jianping Wang,

A. Kate Sasser,

Nedjad Losic,

Steen Lisby,

Linda Basse,

Nikolai C. Brun,

Paul G. Richardson

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1506348

Subject(s) - daratumumab , medicine , multiple myeloma , lenalidomide , adverse effect , refractory (planetary science) , bortezomib , cohort , autologous stem cell transplantation , surgery , gastroenterology , physics , astrobiology

Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1-2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research